Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.21 - $41.31
Previous CloseN/A
Volume154.73K
Average Volume (3M)1.25M
Market Cap
$523.79M
Enterprise Value$904.86M
Total Cash (Recent Filing)$123.08M
Total Debt (Recent Filing)$16.04M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 08, 2025EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.20
Shares Outstanding30,666,780
10 Day Avg. Volume821,793
30 Day Avg. Volume1,246,207
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.74
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.91
Enterprise Value/Ebitda-9.76
Forecast
1Y Price Target
$41.78Price Target Upside144.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
AnaptysBio News
PremiumStock Analysis & Ideas
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
AnaptysBio Reports Strong Progress in Clinical Trials---
Bulls Say, Bears Say
Bulls Say
Company ValuationShares trading with an EV of ~$50MM are seen as undervalued, as NPV analysis of rosnilimab in RA alone suggests $35/share.
Financial PerformanceANAB reported $43.1M in revenue, well above estimates, driven by commercial milestones from GSK’s Jemperli sales.
Long-term Revenue PotentialANAB stands to benefit from long-term royalty revenue into the 2030s due to Jemperli’s exclusivity extending through 2038.
Bears Say
Clinical Trial ResultsANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development.
Market CompetitionAnticipated Keytruda and Opdivo biosimilar launches in 2028 could introduce competitive pressures impacting Jemperli’s growth trajectory beyond 2028.
Potential DelaysThe company is not planning to advance RA into Phase 3 without a partner, indicating potential delays.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $523.79M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Feb 27, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$1.619 by $0.899.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.3.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,666,780 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$0.72 in its last earnings report, beating expectations of -$1.619. Following the earnings report the stock price went up 2.561%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
---
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.78 (144.61% Upside)
$41.78 (144.61% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 146.2%
Last 30 Days ▲ 134.0%
Last 30 Days ▲ 134.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.14%
12-Months-Change
Fundamentals
Return on Equity
-182.71%
Trailing 12-Months
Asset Growth
6.95%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$41.78
▲(144.61% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
-19.88%
reiterated a buy rating 21 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of -19.88% per trade.
---